biomy completes fundraising from SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
(Head office: Shibuya-ku, Tokyo; President: Teppei Konishi; hereinafter "biomy"), a company engaged in drug effect prediction AI and digital therapeutics, announces that it has raised funds from SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (Head office: Kagoshima City, Kagoshima Prefecture; President and CEO: Ryoichi Nagata; hereinafter "SNBL").
■Purpose of Fund Procurement
biomy is a company that provides innovative services to the medical and pharmaceutical industries through the power of AI and biology. biomy aims to discover new digital biomarkers and develop new services by building a big data platform based on the data obtained from the prediction of drug efficacy based on data accumulated in hospitals and health promotion through the provision of healthcare applications, as well as by building a big data platform based on the data obtained from such data. Through this fundraising, biomy plans to strengthen recruitment of human resources, research and development of AI and IT technologies, and build a structure for medical device development.
The underwriter, SNBL is Japan's first contract research organization (CRO) for drug development, established in 1957. As the only company in Japan capable of undertaking all stages of drug development, including basic research and drug discovery, is committed to supporting its partners in new drug development, and we expect high business synergies not only in the deployment of our technologies but also in new business development.
■Our business activities
【AI platform to support anti-tumor drug dosing decisions】
AI analyzes past patient information and selects appropriate cohorts to maximize medication efficacy. AI will predict the prognosis of anti-tumor drugs by taking into account a variety of information that has not been used in the past to determine medication criteria, thereby supporting decision-making on medication.
【Smartphone/VR application for back pain】
It is estimated that more than 80% of people in Japan will experience back pain at least once in their lifetime, and the associated economic loss is estimated to be approximately 3 trillion yen per year. The concept of back pain and other musculoskeletal pain is currently at a historical turning point, as facts that differ from conventional wisdom, such as "exercise is more beneficial than rest" and "psychosocial stress has a strong influence," have been revealed. Focusing on the point that "exercise is more beneficial than rest," we are developing a smartphone/VR application that promotes comprehensive measures against back pain, centered on exercise, in cooperation with Dr. Kou Matsudaira who is the University of Tokyo Hospital professor, and have started demonstration experiments from April 2022 (https:// prtimes.jp/main/html/rd/p/000000006.000082088.html)
■Comments from the Underwriter
Ryoichi Nagata, President and CEO of SNBL.
We have formed a capital alliance with biomy because we share the company's philosophy of advancing biologists' thinking with cutting-edge AI. biomy is not only a group of engineers with advanced AI technology, but also aims to solve essential problems in the entire biotechnology industry by maximizing the potential of AI utilization through deep investigation of issues by biotechnical personnel. S N B L is focusing on the development of in-house DX human resources in order to provide new solutions that will add value to customers, and we have high expectations in terms of in-house AI human resource development through the collaboration with biomy.
Company name: biomy, Inc.
Location: Eclat Shibuya 5F, 3-6-2 Shibuya, Shibuya-ku, Tokyo
CEO: Teppei Konishi
For media inquiries regarding this release, please contact